This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Novel MRI Strategies as a Non-invasive Biomarker in Women With Uterine Fibroids

This study has been completed.
NHS Lothian
Information provided by:
University of Edinburgh Identifier:
First received: September 1, 2008
Last updated: October 22, 2010
Last verified: October 2010

Fibroids are present in up to 80% of women of reproductive age. Associated heavy menstrual bleeding is often an indication for surgery. At present there are no long-term medical treatments for fibroids. There is an unmet need for a pharmacologic agent able to reduce excessive bleeding and other symptoms associated with increased uterine volume, which could prevent or significantly delay surgery without causing significant unwanted hypoestrogenic side effects and allow preservation of fertility.

The purpose of this study is to investigate and validate novel MR imaging as a non-invasive biomarker for monitoring responses to medical interventions aimed at reduction of excessive menstrual bleeding and decrease in uterine/ fibroid volume. MR imaging is non-invasive, does not involve ionizing radiation and new techniques have the potential to resolve tissue detail to near cellular level.

The investigators are aiming to establish the feasibility and reproducibility of novel MR imaging techniques in the evaluation of treatment response in women with fibroids and to provide mechanistic information on whether the reduction in blood flow of uterine/fibroid vasculature in the shrinkage of fibroids is dependent upon subjects being hypoestrogenic.

Condition Intervention Phase
Fibroid Leiomyoma Drug: GnRH analogue (Zoladex) Drug: GnRH antagonist-Cetrorelix Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Novel Magnetic Resonance Imaging Strategies as a Non-invasive Biomarker of Vascular and Extracellular Matrix Morphology in Women With Uterine Fibroids.

Resource links provided by NLM:

Further study details as provided by University of Edinburgh:

Primary Outcome Measures:
  • Uterine and fibroid volume [ Time Frame: 2010 ]

Secondary Outcome Measures:
  • Uterine vascular perfusion, vasculature and extracellular matrix (ECM)content of fibroids. [ Time Frame: 2010 ]

Enrollment: 30
Study Start Date: December 2008
Study Completion Date: September 2010
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
GnRH analogue-Zoladex
Drug: GnRH analogue (Zoladex)
3.6mg subcutaneous implant. Monthly doses x 3.
Active Comparator: 2
GnRH antagonist plus GnRH analogue
Drug: GnRH analogue (Zoladex)
3.6mg subcutaneous implant. Monthly doses x 3.
Drug: GnRH antagonist-Cetrorelix
Subcutaneous injection 3mg x3 over 7 days
Other Name: Cetrotide
No Intervention: 3


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Age>18 years
  • Scheduled for hysterectomy with a fibroid uterus
  • At least one intramural non-pedunculated, submucosal or subserous fibroid(>2cm) or multiple small fibroids (uterine volume>200cm3)
  • Ability to understand and willingness to sign consent form
  • Normal smear within 3 years

Exclusion criteria:

  • Pregnant or lactating
  • Contra indication to MRI
  • Unable to tolerate supine position
  • Diabetes and/or renal or hepatic impairment
  • Contra indication to any of the study medications including gadolinium, MRI contrast
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00746031

United Kingdom
University of Edinburgh/ Royal Infirmary of Edinburgh
Edinburgh, United Kingdom, EH16 4SA
Sponsors and Collaborators
University of Edinburgh
NHS Lothian
Principal Investigator: HILARY OD CRITCHLEY, MBChB;MD;FRCOG University of Edinburgh
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: PROFESSOR HILARY OD CRITCHLEY, UNIVERSITY OF EDINBURGH Identifier: NCT00746031     History of Changes
Other Study ID Numbers: REC number 08/MRE00/30
Study First Received: September 1, 2008
Last Updated: October 22, 2010

Keywords provided by University of Edinburgh:
MR imaging

Additional relevant MeSH terms:
Neoplasms, Muscle Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms, Connective Tissue
Connective Tissue Diseases
Prolactin Release-Inhibiting Factors
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Fertility Agents, Female
Fertility Agents
Reproductive Control Agents
Hormone Antagonists processed this record on September 19, 2017